8-K: Cardiff Oncology Announces Positive Phase 2 Trial Results and Provides Business Update

Cardiff Oncology reported positive Phase 2 trial results for onvansertib in second-line KRAS mutant mCRC and anticipates initial data from a first-line trial by the end of 2024.

Summary

• Cardiff Oncology announced its third quarter 2024 financial results and provided a business update.
• The company published positive Phase 2 trial results of onvansertib in combination with FOLFIRI and bevacizumab (bev) for second-line KRAS mutant mCRC in the Journal of Clinical Oncology.
• A post hoc analysis showed a 7.7 times greater clinical benefit in patients who had not previously received bev, with an ORR of 77% and mPFS of 14.9 months compared to an ORR of 10% and mPFS of 6.6 months in those previously exposed to bev.
• Initial data readout from the first-line RAS-mutated mCRC randomized CRDF-004 trial is expected by the end of 2024.
• The company's current cash resources are projected to fund operations into Q1 2026.
• Cardiff Oncology had approximately $57.7 million in cash, cash equivalents, and short-term investments as of September 30, 2024.
• Net cash used in operating activities for the third quarter of 2024 was approximately $10.5 million, an increase of $2.5 million from the same period in 2023.
• Total operating expenses for the third quarter of 2024 were approximately $12.8 million, an increase of $1.8 million from the same period in 2023.

Sentiment

Score: 8

Explanation: The document presents positive clinical trial results and a solid cash runway, indicating a strong outlook for the company. However, there are also risks associated with clinical trials and the need for future funding.

Positives

• The publication of positive Phase 2 trial results in a prestigious medical journal validates the company's research.
• The significant clinical benefit observed in bev-naive patients is a promising indicator for the first-line trial.
• The company has sufficient cash to fund operations into Q1 2026, providing financial stability.
• The company is making progress in the CRDF-004 trial, leveraging Pfizer's resources and capabilities.

Negatives

• Net cash used in operating activities increased by $2.5 million compared to the same period in 2023.
• Total operating expenses increased by $1.8 million compared to the same period in 2023, primarily due to clinical programs and outside service costs.

Risks

• Clinical trials are lengthy and expensive with uncertain outcomes.
• Trial results may not be predictive of future results.
• Clinical trials may be suspended or discontinued due to unexpected side effects or safety risks.
• The company may need additional financing in the future.
• Business interruptions, such as pandemics and cyber-attacks, could harm the company's financial condition.
• There are uncertainties of government or third-party payer reimbursement.
• The company faces substantial competition and risks related to patent protection and litigation.

Future Outlook

The company anticipates initial data from the first-line RAS-mutated mCRC CRDF-004 trial by the end of 2024 and believes its current cash resources are sufficient to fund operations into Q1 2026.

Management Comments

• Mark Erlander, Ph.D., Chief Executive Officer, stated that the Phase 2 trial results published in the Journal of Clinical Oncology validate the ongoing CRDF-004 trial.
• Mark Erlander also expressed optimism about onvansertib's potential to become a meaningful treatment option for patients with RAS-mutated mCRC.

Industry Context

The announcement highlights progress in the development of new treatments for RAS-mutated mCRC, an area with significant unmet medical need, and positions Cardiff Oncology as a key player in this space. The company's focus on PLK1 inhibition aligns with broader trends in targeted cancer therapies.

Comparison to Industry Standards

• The 77% ORR and 14.9 months mPFS in bev-naive patients in the Phase 2 trial are promising compared to historical outcomes in second-line mCRC.
• The publication in the Journal of Clinical Oncology is a significant achievement, indicating the quality and relevance of the research.
• The company's cash runway into Q1 2026 is relatively strong compared to other clinical-stage biotech companies, providing a longer period to achieve milestones.
• The company's focus on onvansertib in combination with standard of care therapies is a common approach in oncology drug development, aiming to improve efficacy and overcome resistance.

Stakeholder Impact

• Shareholders may react positively to the positive clinical trial results and extended cash runway.
• Patients with RAS-mutated mCRC may benefit from the development of new treatment options.
• Employees may be encouraged by the company's progress and financial stability.

Next Steps

• The company expects initial data readout from the first-line RAS-mutated mCRC CRDF-004 trial by the end of 2024.
• The company will continue to advance its clinical programs and explore additional indications for onvansertib.

Key Dates

Keywords

onvansertib, mCRC, KRAS mutant, clinical trial, PLK1 inhibition, cancer, biotechnology, FOLFIRI, bevacizumab, RAS-mutated